Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Urothelial Carcinoma”

68 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 68 results

Testing effectiveness (Phase 2)Looking for participantsNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Early research (Phase 1)WithdrawnNCT05940844
What this trial is testing

Study of OB-002 in Patients With Refractory Metastatic Cancer

Who this might be right for
Metastatic CancerMetastatic Colorectal CancerMetastatic Pancreatic Cancer+3 more
Orion Biotechnology Polska Sp. z o.o.
Early research (Phase 1)Study completedNCT03538028
What this trial is testing

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Who this might be right for
Cervical CancerMicrosatellite Instability (MSI)-High Endometrial CancerGastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])+14 more
Incyte Biosciences International Sàrl 22
Testing effectiveness (Phase 2)Study completedNCT00066612
What this trial is testing

S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
SWOG Cancer Research Network 45
Testing effectiveness (Phase 2)Ended earlyNCT01331824
What this trial is testing

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

Who this might be right for
Bladder Cancer
Matthew Galsky 22
Not applicableEnded earlyNCT05052372
What this trial is testing

Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib

Who this might be right for
Bladder CancerUrothelial CarcinomaTransitional Cell Carcinoma+10 more
xCures 2
Early research (Phase 1)Active Not RecruitingNCT04007744
What this trial is testing

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Who this might be right for
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8+19 more
Mayo Clinic 36
Testing effectiveness (Phase 2)Ended earlyNCT04856189
What this trial is testing

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Advanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial Carcinoma+1 more
Mamta Parikh 4
Early research (Phase 1)Enrolling By InvitationNCT07218003
What this trial is testing

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Who this might be right for
Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer+7 more
Rondo Therapeutics 149
Testing effectiveness (Phase 2)Active Not RecruitingNCT04164082
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Flat Urothelial Carcinoma In SituNon-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+2 more
National Cancer Institute (NCI) 161
Early research (Phase 1)Study completedNCT03523572
What this trial is testing

Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer

Who this might be right for
Breast CancerUrothelial Carcinoma
Daiichi Sankyo 86
Early research (Phase 1)Study completedNCT03739931
What this trial is testing

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Who this might be right for
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
ModernaTX, Inc. 134
Testing effectiveness (Phase 2)Ended earlyNCT02401542
What this trial is testing

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

Who this might be right for
Locally Advanced or Metastatic Urothelial Cell CarcinomaUrinary Bladder DiseaseUrological Diseases
Rainier Therapeutics 71
Large-scale testing (Phase 3)WithdrawnNCT07342517
What this trial is testing

NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy

Who this might be right for
Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)Urothelial Carcinoma Bladder+2 more
Relmada Therapeutics, Inc.
Testing effectiveness (Phase 2)Study completedNCT01687244
What this trial is testing

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Who this might be right for
Superficial Bladder Cancer
FKD Therapies Oy 40
Testing effectiveness (Phase 2)Study completedNCT02769962
What this trial is testing

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Who this might be right for
Urothelial CarcinomaUrothelial CancerLung Neoplasms+2 more
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)Study completedNCT01620970
What this trial is testing

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Who this might be right for
Transitional Cell Carcinoma of Bladder
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 14
Testing effectiveness (Phase 2)Looking for participantsNCT04977453
What this trial is testing

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorCervical Cancer+3 more
GI Innovation, Inc. 317
Testing effectiveness (Phase 2)Study completedNCT01426126
What this trial is testing

Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum

Who this might be right for
Bladder CancerUreter Cancer
Asan Medical Center 37
Early research (Phase 1)Study completedNCT02808143
What this trial is testing

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Recurrent Bladder CarcinomaStage 0a Bladder Urothelial CarcinomaStage 0is Bladder Urothelial Carcinoma+1 more
Northwestern University 9
Load More Results